α-methylacyl-CoA racemase (P504S)/34βE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy

Human Pathology

Volumn 38, Issue 2, 2007, Pages 332-341

  Sung, Ming Tse ^a,b   Jiang, Zhong ^c   Montironi, Rodolfo ^d   MacLennan, Gregory T ^e   Mazzucchelli, Roberta ^d   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

34 E12; Adenocarcinoma; AMACR; Biomarker; Differential diagnosis; Hormonal therapy; P504S; P63; Prostatic neoplasia

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANTIANDROGEN; CYTOKERATIN; CYTOKERATIN 34BETAE12; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PROTEIN P63; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MINIMAL RESIDUAL DISEASE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; REPRODUCIBILITY OF RESULTS; TRANS-ACTIVATORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 33846251324     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.08.016     Document Type: Article

References (51)

1. Scherr D., Swindle P.W., and Scardino P.T. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61 (2003) 14-24
2. Debruyne F. Hormonal therapy of prostate cancer. Semin Urol Oncol 20 (2002) 4-9
3. Fair W.R., Aprikian A., Sogani P., Reuter V., and Whitmore Jr. W.F. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71 (1993) 1031-1038
4. Hugosson J., Abrahamsson P.A., Ahlgren G., et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 29 (1996) 413-419
5. Soloway M.S., Sharifi R., Wajsman Z., McLeod D., Wood Jr. D.P., and Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154 (1995) 424-428
6. Armas O.A., Aprikian A.G., Melamed J., et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18 (1994) 979-991
7. Bullock M.J., Srigley J.R., Klotz L.H., and Goldenberg S.L. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 26 (2002) 1400-1413
8. Civantos F., Marcial M.A., Banks E.R., et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 75 (1995) 1634-1641
9. Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 (1997) 16-22
10. Vailancourt L., Ttu B., Fradet Y., et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 20 (1996) 86-93
11. Ferdinandusse S., Denis S., Ijlst L., Dacremont G., Waterham H.R., and Wanders R.J. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 41 (2000) 1890-1896
12. Beach R., Gown A.M., De Peralta-Venturina M.N., et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 26 (2002) 1588-1596
13. Jiang Z., Woda B.A., Rock K.L., et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25 (2001) 1397-1404
14. Jiang Z., Wu C.L., Woda B.A., et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 26 (2002) 1169-1174
15. Luo J., Zha S., Gage W.R., et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62 (2002) 2220-2226
16. Rubin M.A., Zhou M., Dhanasekaran S.M., et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287 (2002) 1662-1670
17. Jiang Z., Li C., Fischer A., Dresser K., and Woda B.A. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 123 (2005) 231-236
18. Cheng L., Nagabhushan M., Pretlow T.P., Amini S.B., and Pretlow T.G. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 148 (1996) 1375-1380
19. Cheng L., Pan C.X., Zhang J.T., et al. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res 10 (2004) 3064-3068
20. Zeng G., Hu Z., Kinch M.S., et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163 (2003) 2271-2276
21. Huggins C., and Hodges C.V. Studies on prostatic cancer. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
22. McLeod D.G. Hormonal therapy: historical perspective to future directions. Urology 61 (2003) 3-7
23. Bazinet M., Zheng W., Begin L.R., Aprikian A.G., Karakiewicz P.I., and Elhilali M.M. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49 (1997) 721-725
24. Oesterling J.E., Andrews P.E., Suman V.J., Zincke H., and Myers R.P. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149 (1993) 779-782
25. Paulson D.F. Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy. Urology 48 (1996) 539-540
26. Scolieri M.J., Altman A., and Resnick M.I. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?. J Urol 164 (2000) 1465-1472
27. Xu J., Stolk J.A., Zhang X., et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60 (2000) 1677-1682
28. Kuefer R., Varambally S., Zhou M., et al. Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 161 (2002) 841-848
29. Leav I., McNeal J.E., Ho S.M., and Jiang Z. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Hum Pathol 34 (2003) 228-233
30. Browne T.J., Hirsch M.S., Brodsky G., Welch W.R., Loda M.F., and Rubin M.A. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol 35 (2004) 1462-1468
31. Jiang Z., and Woda B.A. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol 11 (2004) 316-321
32. Amin M.B., Beach R., Gown A.M., and Folpe A.L. Use of a novel immunohistochemical (IHC) panel (P504S, p63 and 34betaE12) in the diagnosis of post-radiation therapy (PRT) prostate cancer (PCa). Mod Pathol 16 (2003) 139
33. Yang X.J., Laven B., Tretiakova M., et al. Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma. Urology 62 (2003) 282-286
34. Suzue K., Montag A.G., Tretiakova M., Yang X.J., and Sahoo S. Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. Am J Clin Pathol 123 (2005) 553-561
35. Zha S., Ferdinandusse S., Denis S., et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 63 (2003) 7365-7376
36. Montironi R., and Schulman C.C. Pathological changes in prostate lesions after androgen manipulation. J Clin Pathol 51 (1998) 5-12
37. Jiang Z., Woda B.A., Wu C.L., and Yang X.J. Discovery and clinical application of a novel prostate cancer marker. Am J Clin Pathol 122 (2004) 275-289
38. Skinnider B.F., Oliva E., Young R.H., and Amin M.B. Expression of α-methylacyl-CoA racemase (P504S) in nephrogenic adenoma. A significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Surg Pathol 28 (2004) 701-705
39. Yang X.J., Wu C.L., Woda B.A., et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 26 (2002) 921-925
40. Wu C.L., Yang X.J., Tretiakova M., et al. Analysis of α-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 35 (2004) 1008-1013
41. Zhou M., Chinnaiyan A.M., Kleer C.G., Lucas P.C., and Rubin M.A. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 26 (2002) 926-931
42. Zhou M., Jiang Z., and Epstein J.I. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol 27 (2003) 772-778
43. Magi-Galluzzi C., Luo J., Isaacs W.B., Hicks J.L., de Marzo A.M., and Epstein J.I. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 27 (2003) 1128-1133
44. Jiang Z., Fanger G.R., Woda B.A., et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 34 (2003) 792-796
45. Kunju L.P., Rubin M.A., Chinnaiyan A.M., and Shah R.B. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol 120 (2003) 737-745
46. Zhou M., Aydin H., Kanane H., and Epstein J.I. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?. Am J Surg Pathol 28 (2004) 239-243
47. Jiang Z., Wu C.L., Woda B.A., et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 45 (2004) 218-225
48. Farinola M.A., and Epstein J.I. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol 35 (2004) 1272-1278
49. Hameed O., Sublett J., and Humphrey P.A. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol 29 (2005) 579-587
50. Nassar A., Amin M.B., Sexton D.G., and Cohen C. Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol 13 (2005) 252-255
51. Kunju L.P., Chinnaiyan A.M., and Shah R.B. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology 47 (2005) 587-596